Sarcomas/TGCT | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Wagner on Risk Factors for Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses known risk factors for developing angiosarcoma.

Dr. Wagner on the Standard of Care in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses the standard of care for patients with angiosarcoma.

Dr. Wagner on Diagnosing Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses the challenge of diagnosing angiosarcoma.

Dr. Wagner on the Value of Cooperative Research Groups in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses the importance of cooperative research groups in angiocarcinoma.

Sylvester Experts Explain the Most Promising Advances in Cancer Research and Treatment Presented at ASCO 2022

July 28th 2022

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Immunotherapy May Represent an Exciting Development in Angiosarcoma Treatment

July 25th 2022

Although systemic treatments are utilized for angiosarcoma, an aggressive and rare subset of a rare cancer, the efficacy achieved with these options is not as good as it needs to be. Immunotherapy may be able to address the unmet need for a systemic treatment in this disease.

Machine Learning Increases Diagnostic Accessibility, Saves Time in Histopathology

July 13th 2022

R. Lor Randall, MD, FACS, shares the successes achieved so far with machine learning in histopathology, explained the positive effect this technology can have on institutions, and advocated for further use of technology to aid treatment advances.

AL102 Monotherapy Demonstrates Early Antitumor Activity in Desmoid Tumors

July 6th 2022

Interim findings from part A of the phase 2/3 RINGSIDE trial indicated that the selective oral gamma-secretase inhibitor, AL102, was found to have favorable tolerability and early antitumor activity in patients with desmoid tumors.

Individualized Care Informs Treatment Modality Choices in Pelvic and Sacral Ewing Carcinoma

June 17th 2022

R. Lor Randall, MD, FACS, discusses the similar benefits offered by radiation and surgery, improved surgical techniques, concerns with morbidity with each approach, and the next steps surgeons and radiation therapists can take to increase patient survival in nonmetastatic pelvic and sacral Ewing carcinoma.

Ripretinib Does Not Provide Superior PFS Benefit Over Sunitinib in Second-line GIST, But Shows Better Tolerability

June 15th 2022

Ripretinib did not result in a significant improvement in progression-free survival over sunitinib in patients with gastrointestinal stromal tumor who were previously treated with imatinib, missing the primary end point of the phase 3 INTRIGUE trial.

Ifosfamide Improves Survival vs Topotecan/Cyclophosphamide in R/R Ewing Sarcoma

June 5th 2022

Ifosfamide induced small improvements in terms of prolonging event-free survival and overall survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma.

Larotrectinib Shows Sustained Efficacy, Safety Benefit in CNS TRK Fusion Cancer

June 5th 2022

Treatment with larotrectinib elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system TRK fusion cancers.

Nirogacestat Significantly Improves PFS in Progressing Desmoid Tumors

May 24th 2022

Nirogacestat was found to significantly improve progression-free survival over placebo when used in the treatment of adult patients with progressing desmoid tumors, meeting the primary end point of the phase 3 DeFi trial.

Selinexor Improves PFS, Time to Next Treatment in Advanced, Metastatic Dedifferentiated Liposarcoma

May 18th 2022

Selinexor monotherapy prolonged progression-free survival, time to next treatment, and reduced pain in patients with advanced, refractory dedifferentiated liposarcoma.

FDA Accepts NDA Resubmission for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors

April 28th 2022

The FDA has accepted for filing the new drug application resubmission for a unique formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have localized, nonmetastatic, solid tumors.

Pathologic Fractures Linked With Poor Outcomes in Osteosarcoma, Ewing Sarcoma

April 15th 2022

For patients with osteosarcoma or Ewing sarcoma who develop pathologic fractures, the prognosis remains poor; however, there is still the possibility for limb salvage therapy.

FDA Grants Orphan Drug Designation to Veyonda for Soft Tissue Sarcoma

March 29th 2022

The FDA has granted an orphan drug designation to Veyonda, a novel proprietary formulation of idronoxil, for use as a potential therapeutic option in patients with soft tissue sarcoma.

Randall Talks Rich AAOS 2022 Program, Packed With Engaging Discussions

March 28th 2022

R. Lor Randall, MD, discusses takeaways from the American Academy of Orthopaedic Surgeons 2022 Annual Meeting.

NDA Resubmitted to FDA for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors

March 24th 2022

A new drug application for a unique formulation of sodium thiosulfate was resubmitted to the FDA for the second time for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have localized, nonmetastatic, solid tumors.

Ultra-Rare Sarcoma Subgroup Sees First Treatment Option

March 7th 2022

Nab-sirolimus became a treatment option for a rare, aggressive soft-tissue sarcoma—malignant perivascular epithelioid cell tumor—following encouraging data in the first prospective clinical trial for this patient population.